TNFR2: A Novel Target for Cancer Immunotherapy

肿瘤微环境 癌症 癌症免疫疗法 免疫疗法 肿瘤坏死因子α 免疫系统 癌症研究 医学 自身免疫 免疫学 免疫检查点 癌细胞 生物 内科学
作者
Éva Scheuring Vanamee,Denise L. Faustman
出处
期刊:Trends in Molecular Medicine [Elsevier BV]
卷期号:23 (11): 1037-1046 被引量:134
标识
DOI:10.1016/j.molmed.2017.09.007
摘要

Tumor antigens have been successfully targeted by monoclonal antibodies, including epidermal growth factor, ERBB2, vascular endothelial growth factor, cytotoxic T lymphocyte antigen 4, CD20, CD30, CD52, and programmed cell death protein 1. Recently developed immune checkpoint inhibitors have shown great promise in eliminating previously hard-to-treat tumors but can cause unwanted autoimmune side effects. In addition, they may have a desirable effect in only approximately 30% of patients. Cancer treatment strategies often aim to target immunosuppressive regulatory T cells (Tregs). Tumor necrosis factor (TNF) receptor 2 (TNFR2) has been deemed both an oncogene and an inducer of Treg expansion. TNFR2 antagonism can boost antitumor immune responses and block the expansion of Tregs. TNFR2 has limited expression across cell types, providing a rationale for its inhibition as a more selective targeted therapy with potentially fewer side effects. Cancer therapies are increasingly relying on combination approaches to increase efficacy. Due to the critical role of TNF superfamily (TNFSF) pathways in immune surveillance and cell proliferation and death, therapies targeting TNFSF receptors might play an important role in putative combination therapies. Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but exhibit variable efficacy and relapse and can induce autoimmunity. Tumor necrosis factor (TNF) receptor 2 (TNFR2) is a signaling molecule found on the surface of a subset of potent regulatory T cells (Tregs) that can activate the proliferation of these cells through nuclear factor kappa B (NF-κB). TNFR2 is also abundantly expressed on the surface of many human tumors. We propose that blocking TNFR2 might target abundant TNFR2+ tumor-infiltrating Tregs and directly kill TNFR2-expressing tumors. We also posit that TNFR2 inhibitors might potentially constitute safer and more targeted alternatives to ICI cancer treatment because the expression of TNFR2 on immune cells, concentrated in the tumor microenvironment of various cancers, appears to be more selective than that of checkpoint molecules. Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but exhibit variable efficacy and relapse and can induce autoimmunity. Tumor necrosis factor (TNF) receptor 2 (TNFR2) is a signaling molecule found on the surface of a subset of potent regulatory T cells (Tregs) that can activate the proliferation of these cells through nuclear factor kappa B (NF-κB). TNFR2 is also abundantly expressed on the surface of many human tumors. We propose that blocking TNFR2 might target abundant TNFR2+ tumor-infiltrating Tregs and directly kill TNFR2-expressing tumors. We also posit that TNFR2 inhibitors might potentially constitute safer and more targeted alternatives to ICI cancer treatment because the expression of TNFR2 on immune cells, concentrated in the tumor microenvironment of various cancers, appears to be more selective than that of checkpoint molecules. the binding of a ligand or drug on a specific cell-surface receptor, thereby producing a physiological response such as proliferation. the binding of a ligand or drug to a cell-surface receptor that inhibits the physiological response and sometimes involves cell death. a mechanism of cell-mediated immune defense whereby an effector cell of the immune system actively lyses a target cell whose membrane-surface antigens have been bound by specific antibodies. In humans ADCC is usually mediated by IgG. cancer antigen-specific antibodies linked to anticancer drugs for the purpose of targeted delivery to the tumor site. rare, potentially fatal skin and mucous membrane disorders associated with IgG or IgA autoantibodies against distinct adhesion molecules of the epidermis or dermal epidermal basement membrane zone, respectively. a type of biological therapy that stimulates or suppresses the immune system to fight cancer. a type of kidney cancer that originates in the lining of the proximal convoluted tubule; the most common type of kidney cancer in adults, responsible for 90–95% of cases. typically CD8+, with the ability to kill its target directly; also referred to as a Teff. the fragment crystallizable region of an antibody. The Fc is the tail region that cannot bind to an antigen but can mediate nonspecific interaction via Fc receptors and proteins of the complement system to activate the immune system. contains both epitope-recognizing Fab fragments of an antibody but not the Fc portion. acute or chronic inflammation of the pituitary gland resulting in varying degrees of pituitary gland failure. commonly, antibodies that block the interaction between T cells and antigen-presenting cells thereby hampering immune activation. antibodies produced by a single clone of immune cells that bind to a single epitope. genes that promote cell survival and cancer growth. In tumors oncogenes are often highly expressed and mutated, which allows their selective targeting. the expressed protein product of an oncogene. loss of multiple pituitary hormones resulting in secondary endocrine failure such as secondary Addison’s disease, infertility, etc. formerly known as suppressor T cells; an important subset of CD4+ T cells responsible for maintaining tolerance to self-antigens and suppressing the deleterious effects of T helper cells. a subset of white blood cells that matures in the thymus and plays an important role in cell-mediated immunity. TNF, the TNFR, and their related superfamily of trimeric ligands and corresponding receptors are transmembrane proteins that play important roles in immune function, cell proliferation, morphogenesis, and cell death.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
赫连烙完成签到,获得积分10
刚刚
深情千雁完成签到,获得积分10
4秒前
Coolkid2001完成签到,获得积分10
5秒前
SunJay发布了新的文献求助10
6秒前
尚影芷完成签到,获得积分10
6秒前
NINI完成签到 ,获得积分10
8秒前
脑洞疼应助干净冰露采纳,获得10
8秒前
小蓝完成签到,获得积分10
9秒前
东晓完成签到,获得积分10
9秒前
雪松完成签到,获得积分10
10秒前
桃子爱学习完成签到,获得积分10
10秒前
bener完成签到,获得积分10
11秒前
乐安完成签到,获得积分10
12秒前
12秒前
yh完成签到,获得积分10
12秒前
苏逸完成签到,获得积分10
14秒前
Hanoi347完成签到,获得积分0
14秒前
Tasia完成签到 ,获得积分10
15秒前
蜀山刀客完成签到,获得积分10
15秒前
兴在路上完成签到,获得积分10
16秒前
有你在前方完成签到,获得积分10
16秒前
Carson完成签到,获得积分10
17秒前
那时花开发布了新的文献求助10
18秒前
18秒前
zcs完成签到,获得积分10
18秒前
隔壁老王完成签到,获得积分10
20秒前
xcwy完成签到,获得积分10
20秒前
默默访冬完成签到 ,获得积分10
20秒前
hebnkygzs完成签到 ,获得积分10
20秒前
肉片牛帅帅完成签到,获得积分10
20秒前
GLF完成签到 ,获得积分10
21秒前
Destiny完成签到,获得积分10
22秒前
landolu完成签到,获得积分10
22秒前
么么完成签到,获得积分10
22秒前
往徕完成签到,获得积分10
24秒前
CipherSage应助kongshuai采纳,获得10
24秒前
乐观谷芹完成签到,获得积分10
24秒前
张大拿完成签到,获得积分10
25秒前
26秒前
jfkyt应助qianlan采纳,获得10
26秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
ズームレンズの光学設計に関する研究 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7282488
求助须知:如何正确求助?哪些是违规求助? 8903239
关于积分的说明 18834053
捐赠科研通 6953287
什么是DOI,文献DOI怎么找? 3207575
关于科研通互助平台的介绍 2377861
邀请新用户注册赠送积分活动 2182761